AbbVie shares weekly forecast: Corporate news flow supports steady climb but resistance caps upside

Traders Union
All News
Stocks
AbbVie advances 0.66% this week

Highlights

Shares of AbbVie edged higher to $265.56 over the past week, maintaining a bullish long-term trend above key averages.
Price action is testing resistance at $266.24, with the stock positioned at the top of its recent weekly range.
Technical signals are mixed with momentum indicators suggesting possible consolidation, and the forecast range for next week is $255.43 to $269.33.

Multifaceted corporate news and partnerships drive positive sentiment this week

A major development for ABBV this week was the September 21, 2026 announcement of a multi-year partnership with Iambic Therapeutics to accelerate discovery of small-molecule therapies using artificial intelligence, as reported by PR Newswire and Investing.com. Additional clinical momentum is building as ABBV is set to present new multiple myeloma pipeline data at the International Myeloma Society Annual Meeting, according to BioSpace. The company also unveiled a charitable PGA TOUR partnership for neurological health and confirmed a $1.73 per share dividend payout, reinforcing its income appeal for investors, according to Yahoo Finance.

Mixed momentum signals as price action tightens near top of range

On the daily chart, price action sits at the very top of the recent weekly range and presses up against resistance at $266.24. Momentum signals are mixed: with RSI in the neutral zone at 59.02 and Stochastic RSI registering a firmly overbought reading of 99.53, while MACD continues to support a positive bias. Support remains at $259.67, with the Ichimoku Kijun at $257.18 as an additional practical level. The momentum character points to a contained move within a narrow range, while volatility has been moderate at 3.27%.

Consolidation expected next week barring breakout above resistance

Next week, the expected range for the stock is $255.43 to $269.33. There is a very high probability of an increase and a very low probability of a decrease. The base case is continued consolidation just below resistance at $266.24. A decisive move above this level would open room toward the upper end of the forecast range, while a failure to hold $259.67 could see shares test support closer to $257.18.

Sholanke Dele, market strategist, sees ABBV shares grinding higher this week but notes the rally now looks stretched near $266 and key resistance at $266.24. He points to a flow of positive news — including the Iambic Therapeutics partnership, clinical data updates, and another strong dividend — as a bolster for near-term sentiment. However, daily chart momentum is mixed: while MACD stays positive, extremely overbought Stochastic RSI at 99.53 and moderate volatility at 3.27% point to a likely rangebound week ahead. Dele expects shares to consolidate just below resistance, and sees $259.67 as the next crucial support to watch if momentum falters. "With upside contained by technical resistance and a string of news already priced in, I’m staying on guard for a reversal unless we see a decisive break above $266.24."

Previously it was reported that AbbVie's collaboration with Iambic was viewed as a potential catalyst for continued bullish price action amid ongoing innovation initiatives. The latest developments—ranging from upcoming clinical data presentations to new partnerships and a dividend payout—now reinforce the case for consolidation just below resistance, placing the spotlight on a potential breakout above $266.24 as the key technical level to watch next week.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.